Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723895 | 1.00 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723004 | 1.00 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13738881 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13739376 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13838775 | 0.88 | F10 (0.79) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL455331 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15203246 | 0.87 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21278838 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL455330 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13738628 | 0.87 | F10 (0.77) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| WO-2012051692-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-04-26 | — | — | WO | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885CYP1A2 18/4885CYP3A4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.